377 related articles for article (PubMed ID: 35602098)
21. The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an
Vecchione G; Grasselli E; Cioffi F; Baldini F; Oliveira PJ; Sardão VA; Cortese K; Lanni A; Voci A; Portincasa P; Vergani L
Front Nutr; 2017; 4():42. PubMed ID: 28971098
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications.
Karimi M; Abiri B; Guest PC; Vafa M
Methods Mol Biol; 2022; 2343():19-35. PubMed ID: 34473313
[TBL] [Abstract][Full Text] [Related]
23. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
24. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.
Cicero AFG; Colletti A; Bellentani S
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142943
[TBL] [Abstract][Full Text] [Related]
25. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
26. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
27. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
28. n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M; Ma LJ; Yang Y; Xiao Z; Wan JB
Crit Rev Food Sci Nutr; 2019; 59(sup1):S116-S129. PubMed ID: 30580553
[TBL] [Abstract][Full Text] [Related]
29. Food components with antifibrotic activity and implications in prevention of liver disease.
Bae M; Park YK; Lee JY
J Nutr Biochem; 2018 May; 55():1-11. PubMed ID: 29268106
[TBL] [Abstract][Full Text] [Related]
30. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats.
Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD
Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707
[TBL] [Abstract][Full Text] [Related]
31. Curcumin Ameliorates Nonalcoholic Fatty Liver Disease through Inhibition of
Lee DE; Lee SJ; Kim SJ; Lee HS; Kwon OS
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31717261
[TBL] [Abstract][Full Text] [Related]
32. Silybin inhibits NLRP3 inflammasome assembly through the NAD
Zhang B; Xu D; She L; Wang Z; Yang N; Sun R; Zhang Y; Yan C; Wei Q; Aa J; Liu B; Wang G; Xie Y
FASEB J; 2018 Feb; 32(2):757-767. PubMed ID: 28970254
[TBL] [Abstract][Full Text] [Related]
33. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review.
Aghemo A; Alekseeva OP; Angelico F; Bakulin IG; Bakulina NV; Bordin D; Bueverov AO; Drapkina OM; Gillessen A; Kagarmanova EM; Korochanskaya NV; Kucheryavii UA; Lazebnik LB; Livzan MA; Maev IV; Martynov AI; Osipenko MF; Sas EI; Starodubova A; Uspensky YP; Vinnitskaya EV; Yakovenko EP; Yakovlev AA
Ann Med; 2022 Dec; 54(1):1548-1560. PubMed ID: 35635048
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease.
Lakhani HV; Sharma D; Dodrill MW; Nawab A; Sharma N; Cottrill CL; Shapiro JI; Sodhi K
Int J Med Sci; 2018; 15(14):1591-1599. PubMed ID: 30588181
[TBL] [Abstract][Full Text] [Related]
35. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
36. Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.
Yang B; Lu L; Zhou D; Fan W; Barbier-Torres L; Steggerda J; Yang H; Yang X
Front Endocrinol (Lausanne); 2022; 13():1007944. PubMed ID: 36267567
[TBL] [Abstract][Full Text] [Related]
37. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
38. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.
Liu Y; Xu W; Zhai T; You J; Chen Y
Acta Pharm Sin B; 2019 Jul; 9(4):745-757. PubMed ID: 31384535
[TBL] [Abstract][Full Text] [Related]
39. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F
J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775
[TBL] [Abstract][Full Text] [Related]
40. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
